Scientists track immune clues in 600 early cancer patients to predict immunotherapy success
NCT ID NCT07427186
First seen Feb 26, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study will follow 600 adults with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who receive immunotherapy before surgery. Researchers will collect blood and tumor samples over time to identify immune system markers that predict how well the treatment works. The goal is to better understand why some patients respond to immunotherapy and others do not, without providing direct treatment benefits to participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Rangueil
Toulouse, 31400, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Larrey
Toulouse, 31400, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.